Related Experiment Video
Updated: Apr 5, 2026
07:34
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
3.3K
[Ipilimumab-induced colitis: A new challenge for gastroenterologists]
Francisco Mesonero1, Antonio López-Sanromán1, Ainhoa Madariaga2
1Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Madrid, España.
Gastroenterologia Y Hepatologia
|August 24, 2015
Summary
Drug-induced colitis from ipilimumab, a monoclonal antibody, presents a significant clinical challenge. Early recognition and management are crucial for patient outcomes in cancer immunotherapy.
Area of Science:
- Immunology
- Gastroenterology
- Oncology
Background:
- Drug-induced enterocolitis is a known clinical entity.
- Monoclonal antibodies, like ipilimumab, represent a new class of drugs causing colitis.
- Ipilimumab targets CTLA-4, enhancing T-cell activation for antitumor effects, but can cause immune-related adverse events.
Purpose of the Study:
- To review ipilimumab-induced colitis.
- To evaluate symptoms, diagnosis, and treatment of this condition.
Main Methods:
- Literature review of ipilimumab-induced colitis.
Main Results:
- Gastrointestinal tract is the most frequent site of immune-related adverse events.
- Adverse events range from diarrhea to severe colitis, perforation, and death.
- Corticosteroids show efficacy in moderate to severe cases, but anti-TNF treatment safety is undefined.
Conclusions:
- Ipilimumab-induced colitis requires familiarity and presents a challenge for gastroenterologists.
- Management strategies are evolving with cancer immunotherapy.
- Further research on anti-TNF treatment safety is needed.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.4K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
685
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
685
01:29Drugs for Treatment of Ulcerative Colitis in IBD
643
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
643
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
759
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
759
01:29Inflammatory Bowel Disease IV: Pharmacological Management
950
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
950
01:21Inflammatory Bowel Disease V: Surgical Management
854
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
854